Research programme: traditional Chinese medicinal therapeutics - Chipscreen

Drug Profile

Research programme: traditional Chinese medicinal therapeutics - Chipscreen

Alternative Names: CS 900210; CS 90034602; CS 90050105; CS 90060103

Latest Information Update: 15 Aug 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chipscreen Biosciences
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Cancer; Osteoporosis; Type 2 diabetes mellitus

Most Recent Events

  • 20 Jul 2004 Preclinical trials in Benign prostatic hyperplasia in China (unspecified route)
  • 20 Jul 2004 Preclinical trials in Cancer in China (unspecified route)
  • 20 Jul 2004 Preclinical trials in Osteoporosis in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top